24 results on '"Curioni-Fontecedro A"'
Search Results
2. MA09.05 Circulating Protein Signatures and Immune Cells Are Predictive and Prognostic Markers for Patients with NSCLC in the SAKK 17/18 Trial
3. Clinically Significant Distress and Physical Problems Detected on a Distress Thermometer are Associated With Survival Among Lung Cancer Patients
4. MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma
5. P1.14-01 Transcriptomic Analysis of Malignant Pleural Mesothelioma (MPM) Reveals Insights for Basic Research and Preclinical Testing
6. OA18.05 Tumor Immune Microenvironment Profiling in Oligometastatic Non-Small Cell Lung Cancer with Brain Metastases
7. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
8. Evolution and Clinical Impact of EGFRMutations in Circulating Free DNA in the BELIEF Trial
9. 18F-FET PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non–Small Cell Lung Cancer
10. 137P Repurposing drug screen of patient-derived malignant pleural mesothelioma cells reveals potential anti-cancer activity
11. Activity of Afatinib in Heavily Pretreated Patients With ERBB2Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
12. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFRmutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
13. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
14. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database
15. P30.02 Salvage Surgery in Patients With Locally Advanced Non-Small Cell Lung Cancer – Outcomes and Longtime Results
16. EP08.03-006 Survival After Radical Treatment of Oligometastatic Non-small Cell Lung Cancer: A Multicenter Analysis
17. An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative
18. Résultats rapportés par les patients (PRO, patient-reported outcomes) de l’étude de phase II CodeBreaK 100 évaluant l’intérêt du sotorasib dans le traitement du cancer du poumon non à petites cellules (CPNPC) avec mutation KRAS p.G12C
19. CheckMate 817 : nivolumab + ipilimumab en première ligne chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) avancé avec un ECOG PS 2 et autres populations particulières
20. P30.01 Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01)
21. P2.01-51 Study of CD26/DPP4 Expression in a Large Series of Non-Small Cell Lung Cancer Patients
22. MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry
23. P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC
24. P3.04-22 Response of Brain Metastases in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy and Brain Directed Radiotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.